Browsing by Author "Díaz Álvarez, Pamela Alejandra"

Now showing 1 - 4 of 4
  • No Thumbnail Available
    Item
    A Competence-Based Model for Teaching Rheumatology in Undergraduate Medical Students in Pontificia Universidad Catolica De Chile: A Five Years Experience
    (2012) Díaz Álvarez, Pamela Alejandra; Cuellar, Carolina; Gutiérrez Torres, Miguel Alejandro; Cisternas Martínez, Marcela Carolina
  • Thumbnail Image
    Item
    Inflammatory back pain for diagnosis of axial psoriatic arthritis: a systematic review and meta-analysis (Protocol)
    (2024) Díaz Álvarez, Pamela Alejandra; Briones Carvajal, Juan Rodrigo; Taylor, Kathryn
  • Thumbnail Image
    Item
    Seeing is believing: Smart use of musculoskeletal ultrasound in rheumatology practice
    (2023) Koppikar, Sahil; Díaz Álvarez, Pamela Alejandra; Kaeley, Gurjit S.; Eder, Lihi
    Musculoskeletal ultrasonography has become an increasingly valuable tool as a complement to the physical exam in rheumatology practice. Its point-of-care access, low cost, safety, portability, and reliability in trained hands, make this technique especially useful in patients with inflammatory arthritis. Growing evidence has demonstrated the value of musculoskeletal ultrasound in the detection of inflammatory and structural changes in patients with joint pain without obvious joint swelling, in differentiating various inflammatory diagnoses, in the monitoring of inflammatory arthritis, and interventional procedures. The potential role of ultrasound guiding treat-to-target strategies or tapering treatment in inflammatory arthritis requires further research. However, musculoskeletal ultrasound can also have pitfalls and limitations that a clinician should be aware of.
  • No Thumbnail Available
    Item
    The Persistence of Biologic Therapies for Psoriatic Arthritis: A Narrative Review
    (Wolters Kluwer Health, Inc., 2024) Jasmen Espinoza, Magdalena Sofía; García, Dominga; Ibáñez, Sebastián; Díaz Álvarez, Pamela Alejandra
    Drug persistence is a crucial measure of long-term efficacy, safety, and patient satisfaction. Lack of persistence can increase healthcare costs and morbidity and mortality rates. This review aimed to consolidate available data on drug persistence for various biological treatments used as the primary intervention for psoriatic arthritis and identify factors associated with nonpersistence. Reports indicate variable 1-year persistence rates for biologic therapies, ranging from 37% to 73%. Specifically, tumor necrosis factor inhibitors have shown fluctuating 1-year persistence rates ranging from 32% to 85%. IL-12/23 and IL-23 inhibitors demonstrate persistence rates of 25% to 89%, whereas data for IL-17 and JAK inhibitors are more limited, ranging from 51% to 77%. Factors such as female sex and a higher burden of comorbidities have been associated with an increased risk of nonpersistence, although evidence regarding other factors remains scarce. The significant variability in reported persistence rates may be attributed to differences in treatment gaps and methodologies across studies. Addressing and mitigating the factors leading to nonpersistence is essential for improving treatment outcomes in psoriatic arthritis.